Irish generics association gets new name
This article was originally published in Scrip
Executive Summary
The Association of Pharmaceutical Manufacturers in Ireland (APMI) has been relaunched as the Irish Generic Medicines Association (IGMA), a name that is designed to reflect its specific remit, scope of functions and responsibilities, it announced. The association represents seven companies employing 2,300+ people in Ireland. The member companies are Accord Healthcare, Actavis Ireland, Clonmel Healthcare Ltd, Fannin Ltd, Hospira Ireland, Rowex Ltd and Pinewood Healthcare. The organization's primary purpose is to promote and support the supply of affordable medicines in Ireland, and is the recognized negotiating body on supply and pricing of generics in the country. Among other things, it is calling for new legislation in Ireland on biosimilars and high-tech generic molecules.
You may also be interested in...
New Irish Generics Body Wants “Fundamental” Reform Of Medicines Procurement
Two generic industry associations have merged to form a single body that includes the largest generic companies in Ireland. Medicines For Ireland has marked its creation by saying it plans to push for a reform of Irish medicines procurement policies, particularly in areas such as tackling drug shortages, and has called for action to promote the use of biosimilars.
New Irish Generics Body Wants “Fundamental” Reform Of Medicines Procurement
Two generic industry associations have merged to form a single body that includes the largest generic companies in Ireland. Medicines For Ireland has marked its creation by saying it plans to push for a reform of Irish medicines procurement policies, particularly in areas such as tackling drug shortages, and has called for action to promote the use of biosimilars.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”